Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from central Asia and was spread throughout Europe and Anatolia by human migrations.
Uyguner O, Goicoechea de Jorge E, Cefle A, Baykal T, Kayserili H, Cefle K, Demirkol M, Yuksel-Apak M, Rodriguez de Córdoba S, Wollnik B. Uyguner O, et al. Among authors: cefle k, cefle a. J Inherit Metab Dis. 2003;26(1):17-23. doi: 10.1023/a:1024063126954. J Inherit Metab Dis. 2003. PMID: 12872836 Clinical Trial.
A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.
Yazici A, Özdemir Işık Ö, Dalkılıç E, Koca SS, Pehlivan Y, Şenel S, Inanc N, Akar S, Yılmaz S, Soysal Gündüz Ö, Cefle A, Karakaş ÖF, Onen F. Yazici A, et al. Among authors: cefle a. Sci Rep. 2022 Dec 20;12(1):21972. doi: 10.1038/s41598-022-26106-0. Sci Rep. 2022. PMID: 36539458 Free PMC article.
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Jacobsson L, Loft AG, Iannone F, Fagerli KM, Vencovsky J, Santos MJ, Möller B, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Cefle A, Eklund K, Codreanu C, Jones G, van der Sande M, Wallman JK, Sebastiani M, Michelsen B, Závada J, Nissen MJ, Sanchez-Piedra C, Tomšič M, Love TJ, Relas H, Mogosan C, Hetland ML, Østergaard M. Ørnbjerg LM, et al. Among authors: cefle a. J Rheumatol. 2024 Apr 1;51(4):378-389. doi: 10.3899/jrheum.2023-0764. J Rheumatol. 2024. PMID: 38224992 Free article.
Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy.
Carmona FD, Coit P, Saruhan-Direskeneli G, Hernández-Rodríguez J, Cid MC, Solans R, Castañeda S, Vaglio A, Direskeneli H, Merkel PA, Boiardi L, Salvarani C, González-Gay MA, Martín J, Sawalha AH; Spanish GCA Study Group; Italian GCA Study Group; Turkish Takayasu Study Group; Vasculitis Clinical Research Consortium. Carmona FD, et al. Sci Rep. 2017 Apr 5;7:46012. doi: 10.1038/srep46012. Sci Rep. 2017. PMID: 28378796 Free PMC article. No abstract available.
Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.
Karataş A, Pişkin Sağir R, Koca SS, Dalkiliç E, Can G, Pehlivan Y, Yazici A, Inanç N, Cefle A, Ertürk Z, Akar S, Şenel S, Birlik M, Akkoç N, Önen F. Karataş A, et al. Among authors: cefle a. Turk J Med Sci. 2023 Jun 21;53(5):1321-1329. doi: 10.55730/1300-0144.5698. eCollection 2023. Turk J Med Sci. 2023. PMID: 38813042 Free PMC article.
112 results